Agilent Partners with OmixAI to Expand AI-Driven Proteomics in South Korea

Agilent Technologies Inc. announced a three-year strategic collaboration with OmixAI to advance next-generation precision medicine through AI-driven proteomics research, strengthening Agilent’s presence in fast-growing life sciences markets in Asia. 

The collaboration focuses on the joint development of automated sample preparation workflows, integrating Agilent’s Bravo Automated Liquid Handling Platform with OmixAI’s proprietary multimodal database and AI-powered experimentation capabilities. The approach is designed to harness AI, enabling large-scale analysis of complex biological data from living organisms, helping generate actionable insights that advance translational research and drive long-term clinical impact. 

Under the agreement, the companies will explore joint research initiatives in targeted protein degradation (TPD), biomarker discovery and emerging therapeutic modalities. The work aims to accelerate the identification of circulating biomarkers that may improve therapeutic outcomes. Both parties also plan to establish scalable, high-throughput standards for protein profiling across South Korea’s research and biopharmaceutical ecosystems.

"We are thrilled to partner with Agilent to pioneer an innovative self-driving lab powered by Physical AI. By leveraging our proprietary The Cancer Surfaceome Atlas (TCSA) alongside Agilent’s leading automation technology, we aim to drastically accelerate the development of next-generation ADC and TPD therapeutics. This collaboration reinforces our commitment to establishing South Korea as a global leader in AI-driven proteomics and precision medicine," said Park Jong Bae, Chief Technology Officer of OmixAI.

“South Korea is an important growth market for precision medicine, and this collaboration further positions Agilent to scale innovation with speed and rigor locally. Together with OmixAI, we are strengthening our differentiated portfolio by expanding cutting-edge, AI-enabled proteomics workflows that support translational research, paving the way to the development of future therapeutics and support long-term customer adoption and value creation,” said Kang Hyun Hoo, Country General Manager of Agilent Technologies Korea.